OPR - Delayed Quote • USD CRBU Oct 2024 5.000 put (CRBU241018P00005000) Follow 1.6000 0.0000 (0.00%) As of April 24 at 9:47 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for CRBU241018P00005000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: CRBU Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus With 65% institutional ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) is a favorite amongst the big guns All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy 11 Oversold NASDAQ Stocks To Buy Right Now Why Caribou Biosciences Stock Is Crashing Today Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting 12 $10 Stocks That Will Triple Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold Steven Cohen's Point72 Adds Caribou Biosciences Inc to Its Portfolio
